@article {7072,
	title = {International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma},
	journal = {The Lancet Oncology},
	volume = {17},
	year = {2016},
	note = {Cited By :9Export Date: 18 February 2017References: Kumar, S.K., Dispenzieri, A., Lacy, M.Q., Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients (2013) Leukemia, 28, pp. 1122-1208;Pozzi, S., Marcheselli, L., Bari, A., Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis (2013) Br J Haematol, 163, pp. 40-46; 
Rajkumar, S.V., IV. Initial treatment of multiple myeloma (2013) Hematol Oncol, 31, pp. 33-37; 
Laubach, J., Hideshima, T., Richardson, P., Anderson, K., Clinical translation in multiple myeloma: from bench to bedside (2013) Semin Oncol, 40, pp. 549-553; 
Hari, P.N., McCarthy, P.L., Multiple myeloma: future directions in autologous transplantation and novel agents (2013) Biol Blood Marrow Transplant, 19, pp. 20-25; 
Fonseca, R., Monge, J., Myeloma: classification and risk assessment (2013) Semin Oncol, 40, pp. 554-566; 
Chng, W.J., Dispenzieri, A., Chim, C.S., IMWG consensus on risk stratification in multiple myeloma (2013) Leukemia, 28, pp. 269-277; 
Palumbo, A., Sezer, O., Kyle, R., International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation (2009) Leukemia, 23, pp. 1716-1730; 
Dimopoulos, M., Terpos, E., Comenzo, R.L., International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple myeloma (2009) Leukemia, 23, pp. 1545-1556; 
Rajkumar, S.V., Dimopoulos, M.A., Palumbo, A., International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma (2014) Lancet Oncol, 15, pp. e538-e548; 
Durie, B.G., Harousseau, J.L., Miguel, J.S., International uniform response criteria for multiple myeloma (2006) Leukemia, 20, pp. 1467-1473; 
Chee, C.E., Kumar, S., Larson, D.R., The importance of bone marrow examination in determining complete response to therapy in patients with multiple myeloma (2009) Blood, 114, pp. 2617-2618; 
Kapoor, P., Kumar, S.K., Dispenzieri, A., Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma (2013) J Clin Oncol, 31, pp. 4529-4535; 
Rajkumar, S.V., Harousseau, J.L., Durie, B., Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1 (2011) Blood, 117, pp. 4691-4695; 
Attal, M., Harousseau, J.L., Stoppa, A.M., A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome (1996) N Engl J Med, 335, pp. 91-97; 
Child, J.A., Morgan, G.J., Davies, F.E., High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma (2003) N Engl J Med, 348, pp. 1875-1883; 
Attal, M., Lauwers-Cances, V., Marit, G., Lenalidomide maintenance after stem-cell transplantation for multiple myeloma (2012) N Engl J Med, 366, pp. 1782-1791; 
McCarthy, P.L., Owzar, K., Hofmeister, C.C., Lenalidomide after stem-cell transplantation for multiple myeloma (2012) N Engl J Med, 366, pp. 1770-1781; 
Jakubowiak, A.J., Dytfeld, D., Griffith, K.A., A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma (2012) Blood, 120, pp. 1801-1809; 
Kumar, S., Flinn, I., Richardson, P.G., Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma (2012) Blood, 119, pp. 4375-4382; 
Cavo, M., Tacchetti, P., Patriarca, F., Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study (2010) Lancet, 376, pp. 2075-2085; 
Gay, F., Larocca, A., Wijermans, P., Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients (2011) Blood, 117, pp. 3025-3031; 
Harousseau, J.L., Palumbo, A., Richardson, P.G., Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone (2010) Blood, 116, pp. 3743-3750; 
Chanan-Khan, A.A., Giralt, S., Importance of achieving a complete response in multiple myeloma, and the impact of novel agents (2010) J Clin Oncol, 28, pp. 2612-2624; 
Harousseau, J.L., Attal, M., Avet-Loiseau, H., The role of complete response in multiple myeloma (2009) Blood, 114, pp. 3139-3146; 
Paiva, B., Vidriales, M.B., Rosinol, L., A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control (2013) Leukemia, 27, pp. 2056-2061; 
van de Velde, H.J., Liu, X., Chen, G., Cakana, A., Deraedt, W., Bayssas, M., Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma (2007) Haematologica, 92, pp. 1399-1406; 
Paiva, B., Vidriales, M.B., Cervero, J., Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation (2008) Blood, 112, pp. 4017-4023; 
Paiva, B., Martinez-Lopez, J., Vidriales, M.B., Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma (2011) J Clin Oncol, 29, pp. 1627-1633; 
Paiva, B., Gutierrez, N.C., Rosinol, L., High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma (2012) Blood, 119, pp. 687-691; 
Zamagni, E., Patriarca, F., Nanni, C., Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation (2011) Blood, 118, pp. 5989-5995; 
Rawstron, A.C., Child, J.A., de Tute, R.M., Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study (2013) J Clin Oncol, 31, pp. 2540-2547; 
Puig, N., Sarasquete, M.E., Balanzategui, A., Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry (2014) Leukemia, 28, pp. 391-397; 
Martinez-Lopez, J., Lahuerta, J.J., Pepin, F., Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma (2014) Blood, 123, pp. 3073-3079; 
Paiva, B., Puig, N., Garcia-Sanz, R., San Miguel, J.F., Is this the time to introduce minimal residual disease in multiple myeloma clinical practice? (2015) Clin Cancer Res, 21, pp. 2001-2008; 
Rawstron, A.C., Orfao, A., Beksac, M., Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders (2008) Haematologica, 93, pp. 431-438; 
Puig, N., Sarasquete, M.E., Alcoceba, M., Kappa deleting element as an alternative molecular target for minimal residual disease assessment by real-time quantitative PCR in patients with multiple myeloma (2012) Eur J Haematol, 89, pp. 328-335; 
Martinez-Sanchez, P., Montejano, L., Sarasquete, M.E., Evaluation of minimal residual disease in multiple myeloma patients by fluorescent-polymerase chain reaction: the prognostic impact of achieving molecular response (2008) Br J Haematol, 142, pp. 766-774; 
Sarasquete, M.E., Garc{\'\i}a-Sanz, R., Gonzalez, D., Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry (2005) Haematologica, 90, pp. 1365-1372; 
Ladetto, M., Donovan, J.W., Harig, S., Real-time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in multiple myeloma (2000) Biol Blood Marrow Transplant, 6, pp. 241-253; 
van Dongen, J.J., Lhermitte, L., Bottcher, S., EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes (2012) Leukemia, 26, pp. 1908-1975; 
Kalina, T., Flores-Montero, J., van der Velden, V.H., EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols (2012) Leukemia, 26, pp. 1986-2010; 
Paiva, B., Almeida, J., Perez-Andres, M., Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders (2010) Cytometry B Clin Cytom, 78, pp. 239-252; 
Paiva, B., Vidriales, M.B., Perez, J.J., Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients (2009) Haematologica, 94, pp. 1599-1602; 
Morice, W.G., Hanson, C.A., Kumar, S., Frederick, L.A., Lesnick, C.E., Greipp, P.R., Novel multi-parameter flow cytometry sensitively detects phenotypically distinct plasma cell subsets in plasma cell proliferative disorders (2007) Leukemia, 21, pp. 2043-2046; 
San Miguel, J.F., Almeida, J., Mateo, G., Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome (2002) Blood, 99, pp. 1853-1856; 
Rawstron, A.C., Davies, F.E., DasGupta, R., Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation (2002) Blood, 100, pp. 3095-3100; 
Mateo, G., Montalban, M.A., Vidriales, M.B., Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy (2008) J Clin Oncol, 26, pp. 2737-2744; 
Paiva, B., Gutierrez, N.C., Chen, X., Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients (2012) Leukemia, 26, pp. 1862-1869; 
P{\'e}rez-Persona, E., Vidriales, M.B., Mateo, G., New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells (2007) Blood, 110, pp. 2586-2592; 
Paiva, B., Azpilikueta, A., Puig, N., PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma (2015) Leukemia, 29, pp. 2110-2113; 
Raja, K.R., Kovarova, L., Hajek, R., Review of phenotypic markers used in flow cytometric analysis of MGUS and MM, and applicability of flow cytometry in other plasma cell disorders (2010) Br J Haematol, 149, pp. 334-351; 
Stetler-Stevenson, M., Paiva, B., Stoolman, L., Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition (2015) Cytometry B Clin Cytom, 90, pp. 26-30; 
Flanders, A., Stetler-Stevenson, M., Landgren, O., Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity (2013) Blood, 122, pp. 1088-1089; 
Rawstron, A.C., Paiva, B., Stetler-Stevenson, M., Assessment of minimal residual disease in myeloma and the need for a consensus approach (2016) Cytometry B Clin Cytom, 90, pp. 21-25; 
Barlogie, B., Anaissie, E., Haessler, J., Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma (2008) Cancer, 113, pp. 355-359; 
Roussel, M., Lauwers-Cances, V., Robillard, N., Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myelome (2014) J Clin Oncol, 32, pp. 2712-2717; 
Arana, P., Paiva, B., Puig, N., Prognostic value of immune profiling multiple myeloma patients during minimal residual disease monitoring in the Pethema/GEM2010MAS65 study (2015) Blood, 126, p. 721; 
van Dongen, J.J., van der Velden, V.H., Bruggemann, M., Orfao, A., Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies (2015) Blood, 125, pp. 3996-4009; 
Paiva, B., van Dongen, J.J., Orfao, A., New criteria for response assessment: role of minimal residual disease in multiple myeloma (2015) Blood, 125, pp. 3059-3068; 
Korthals, M., Sehnke, N., Kronenwett, R., The level of minimal residual disease in the bone marrow of patients with multiple myeloma before high-dose therapy and autologous blood stem cell transplantation is an independent predictive parameter (2012) Biol Blood Marrow Transplant, 18, pp. 423-431; 
Putkonen, M., Kairisto, V., Juvonen, V., Depth of response assessed by quantitative ASO-PCR predicts the outcome after stem cell transplantation in multiple myeloma (2010) Eur J Haematol, 85, pp. 416-423; 
Ladetto, M., Pagliano, G., Ferrero, S., Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma (2010) J Clin Oncol, 28, pp. 2077-2084; 
Martinelli, G., Terragna, C., Zamagni, E., Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma (2000) J Clin Oncol, 18, pp. 2273-2281; 
Bakkus, M.H., Bouko, Y., Samson, D., Post-transplantation tumour load in bone marrow, as assessed by quantitative ASO-PCR, is a prognostic parameter in multiple myeloma (2004) Br J Haematol, 126, pp. 665-674; 
Lipinski, E., Cremer, F.W., Ho, A.D., Goldschmidt, H., Moos, M., Molecular monitoring of the tumor load predicts progressive disease in patients with multiple myeloma after high-dose therapy with autologous peripheral blood stem cell transplantation (2001) Bone Marrow Transplant, 28, pp. 957-962; 
Galimberti, S., Benedetti, E., Morabito, F., Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation (2005) Leuk Res, 29, pp. 961-966; 
Martinez-Lopez, J., Fernandez-Redondo, E., Garcia-Sanz, R., Clinical applicability and prognostic significance of molecular response assessed by fluorescent-PCR of immunoglobulin genes in multiple myeloma. Results from a GEM/PETHEMA study (2013) Br J Haematol, 163, pp. 581-589; 
Puig, N., Sarasquete, M.E., Alcoceba, M., The use of CD138 positively selected marrow samples increases the applicability of minimal residual disease assessment by PCR in patients with multiple myeloma (2013) Ann Hematol, 92, pp. 97-100; 
Drandi, D., Kubiczkova-Besse, L., Ferrero, S., Minimal residual disease detection by droplet digital PCR in multiple myeloma, mantle cell lymphoma, and follicular lymphoma: a comparison with real-time PCR (2015) J Mol Diag, 17, pp. 652-660; 
Ladetto, M., Br{\"u}ggemann, M., Monitillo, L., Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders (2014) Leukemia, 28, pp. 1299-1307; 
Avet-Loiseau, H., Corre, J., Lauwers-Cances, V., Evaluation of minimal residual disease (MRD) by next generation sequencing (NGS) is highly predictive of progression free survival in the IFM/DFCI 2009 Trial (2015) Blood, 126, p. 191; 
Korde, N., Roschewski, M., Zingone, A., Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma (2015) JAMA Oncol, 1, pp. 746-754; 
Ghimire, K., Rajkumar, S.V., Dispenzieri, A., Incidence and survival outcomes of extramedullary myeloma (2013) Blood, 122, p. 3141; 
Usmani, S.Z., Heuck, C., Mitchell, A., Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents (2012) Haematologica, 97, pp. 1761-1767; 
Blad{\'e}, J., de Larrea, C.F., Rosi{\~n}ol, L., Extramedullary involvement in multiple myeloma (2012) Haematologica, 97, pp. 1618-1619; 
Short, K.D., Rajkumar, S.V., Larson, D., Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma (2011) Leukemia, 25, pp. 906-908; 
Varettoni, M., Corso, A., Pica, G., Mangiacavalli, S., Pascutto, C., Lazzarino, M., Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients (2010) Ann Oncol, 21, pp. 325-330; 
Sheth, N., Yeung, J., Chang, H., p53 nuclear accumulation is associated with extramedullary progression of multiple myeloma (2009) Leuk Res, 33, pp. 1357-1360; 
Dores, G.M., Landgren, O., McGlynn, K.A., Curtis, R.E., Linet, M.S., Devesa, S.S., Plasmacytoma of bone, extramedullary plasmacytoma, and multiple myeloma: incidence and survival in the United States, 1992{\textendash}2004 (2009) Br J Haematol, 144, pp. 86-94; 
Usmani, S.Z., Mitchell, A., Waheed, S., Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3 (2013) Blood, 121, pp. 1819-1823; 
Bartel, T.B., Haessler, J., Brown, T.L., F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma (2009) Blood, 114, pp. 2068-2076; 
van Lammeren-Venema, D., Regelink, J.C., Riphagen, I.I., Zweegman, S., Hoekstra, O.S., Zijlstra, J.M., 18F-fluoro-deoxyglucose positron emission tomography in assessment of myeloma-related bone disease: a systematic review (2012) Cancer, 118, pp. 1971-1981; 
Elliott, B.M., Peti, S., Osman, K., Combining FDG-PET/CT with laboratory data yields superior results for prediction of relapse in multiple myeloma (2011) Eur J Haematol, 86, pp. 289-298; 
Zamagni, E., Nanni, C., Mancuso, K., PET/CT improves the definition of complete response and allows to detect otherwise unidentifiable skeletal progression in multiple myeloma (2015) Clin Cancer Res, 21, pp. 4384-4390; 
Moreau, P., Attal, M., Karlin, L., Prospective evaluation of MRI and PET-CT at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM/DFCI 2009 trial (2015) Blood, 126, p. 395; 
Hillengass, J., Landgren, O., Challenges and opportunities of novel imaging techniques in monoclonal plasma cell disorders: imaging {\textquotedblleft}early myeloma{\textquotedblright} (2013) Leuk Lymphoma, 54, pp. 1355-1363; 
Walker, R., Barlogie, B., Haessler, J., Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications (2007) J Clin Oncol, 25, pp. 1121-1128; 
Hillengass, J., Ayyaz, S., Kilk, K., Changes in magnetic resonance imaging before and after autologous stem cell transplantation correlate with response and survival in multiple myeloma (2012) Haematologica, 97, pp. 1757-1760; 
Dimopoulos, M.A., Hillengass, J., Usmani, S., Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement (2015) J Clin Oncol, 33, pp. 657-664; 
Derlin, T., Peldschus, K., Munster, S., Comparative diagnostic performance of 18F-FDG PET/CT versus whole-body MRI for determination of remission status in multiple myeloma after stem cell transplantation (2013) Eur Radiol, 23, pp. 570-578; 
Walker, R.C., Brown, T.L., Jones-Jackson, L.B., De Blanche, L., Bartel, T., Imaging of multiple myeloma and related plasma cell dyscrasias (2012) J Nucl Med, 53, pp. 1091-1101; 
Derlin, T., Weber, C., Habermann, C.R., 18F-FDG PET/CT for detection and localization of residual or recurrent disease in patients with multiple myeloma after stem cell transplantation (2012) Eur J Nucl Med Mol Imaging, 39, pp. 493-500; 
Shortt, C.P., Gleeson, T.G., Breen, K.A., Whole-Body MRI versus PET in assessment of multiple myeloma disease activity (2009) AJR Am J Roentgenol, 192, pp. 980-986; 
Barrington, S.F., Mikhaeel, N.G., Kostakoglu, L., Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group (2014) J Clin Oncol, 32, pp. 3048-3058; 
Paiva, B., Chandia, M., Puig, N., The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma (2015) Haematologica, 100, pp. e53-e55; 
Nanni, C., Zamagni, E., Versari, A., Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe) (2015) Eur J Nucl Med Mol Imaging, 43, pp. 414-421; 
Fraioli, F., Punwani, S., Clinical and research applications of simultaneous positron emission tomography and MRI (2014) Br J Radiol, 87, p. 20130464; 
Pawlyn, C., Fowkes, L., Otero, S., Whole-body diffusion-weighted MRI: a new gold standard for assessing disease burden in patients with multiple myeloma? (2016) Leukemia, 30, pp. 1446-1448; 
McCudden, C.R., Voorhees, P.M., Hainsworth, S.A., Interference of monoclonal antibody therapies with serum protein electrophoresis tests (2010) Clin Chem, 56, pp. 1897-1899; 
Genzen, J.R., Kawaguchi, K.R., Furman, R.R., Detection of a monoclonal antibody therapy (ofatumumab) by serum protein and immunofixation electrophoresis (2011) Br J Haematol, 155, pp. 123-125; 
Axel, A.E., McCudden, C.R., Xie, H., Hall, B.M., Sasser, A.K., Development of clinical assay to mitigate daratumumab, an IgG1κ monoclonal antibody, interference with serum immunofixation (IFE) and clinical assessment of M-protein response in multiple myeloma (2014) Cancer Res, 74, p. 2563; 
Mills, J.R., Barnidge, D.R., Murray, D.L., Detecting monoclonal immunoglobulins in human serum using mass spectrometry (2015) Methods, 81, pp. 56-65; 
Walz, S., Stickel, J.S., Kowalewski, D.J., The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell-based immunotherapy (2015) Blood, 126, pp. 1203-1213; 
Nowakowski, G.S., Witzig, T.E., Dingli, D., Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma (2005) Blood, 106, pp. 2276-2279; 
Gonsalves, W.I., Morice, W.G., Rajkumar, V., Quantification of clonal circulating plasma cells in relapsed multiple myeloma (2014) Br J Haematol, 167, pp. 500-505; 
Gonsalves, W.I., Rajkumar, S.V., Gupta, V., Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma (2014) Leukemia, 28, pp. 2060-3005; 
Korthals, M., Sehnke, N., Kronenwett, R., Molecular monitoring of minimal residual disease in the peripheral blood of patients with multiple myeloma (2013) Biol Blood Marrow Transplant, 19, pp. 1109-1115; 
Vij, R., Mazumder, A., Klinger, M., Deep sequencing reveals myeloma cells in peripheral blood in majority of multiple myeloma patients (2014) Clin Lymphoma Myeloma Leuk, 14, pp. 131-139; 
Kubiczkova-Besse, L., Drandi, D., Sedlarikova, L., Cell-free DNA for minimal residual disease monitoring for multiple myeloma patients (2014) Blood, 124, p. 3423; 
Rustad, E.H., Dai, H.Y., Coward, E., Detection and monitoring of BRAF and NRAS mutant clones in myeloma patients by digital PCR of circulating DNA (2015) Blood, 126, p. 4196; 
Gimondi, S., Cavan{\`e}, A., Vendramin, A., Identification of clonal Igh gene rearrangements by high-throughput sequencing of cell free DNA in multiple myeloma patients (2015) Blood, 126, p. 2987; 
Kaedbey, R., Kis, O., Danesh, A., Noninvasive diagnosis of actionable mutations by deep sequencing of circulating cell free DNA (cfDNA) in multiple myeloma (MM) (2015) Clin Lymphoma Myeloma Leuk, 15, pp. e45-e46; 
Tovar, N., Fern{\'a}ndez de Larrea, C., Elena, M., Prognostic impact of serum immunoglobulin heavy/light chain ratio in patients with multiple myeloma in complete remission after autologous stem cell transplantation (2012) Biol Blood Marrow Transplant, 18, pp. 1076-1079; 
Ludwig, H., Milosavljevic, D., Zojer, N., Immunoglobulin heavy/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients (2013) Leukemia, 27, pp. 213-219; 
van Rhee, F., Bolejack, V., Hollmig, K., High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis (2007) Blood, 110, pp. 827-832; 
Zhan, F., Barlogie, B., Arzoumanian, V., Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis (2007) Blood, 109, pp. 1692-1700; 
Dejoie, T., Attal, M., Moreau, P., Harousseau, J.L., Avet-Loiseau, H., Comparison of serum free light chain and urine electrophoresis for the detection of the light chain component of monoclonal immunoglobulins in light chain and intact immunoglobulin multiple myeloma (2016) Haematologica, 101, pp. 356-362; 
Dispenzieri, A., Kyle, R., Merlini, G., International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders (2009) Leukemia, 23, pp. 215-224; 
Dispenzieri, A., Zhang, L., Katzmann, J.A., Appraisal of immunoglobulin free light chain as a marker of response (2008) Blood, 111, pp. 4908-4915
},
	month = {2016},
	pages = {e328 - e346},
	abstract = {Treatment of multiple myeloma has substantially changed over the past decade with the introduction of several classes of new effective drugs that have greatly improved the rates and depth of response. Response criteria in multiple myeloma were developed to use serum and urine assessment of monoclonal proteins and bone marrow assessment (which is relatively insensitive). Given the high rates of complete response seen in patients with multiple myeloma with new treatment approaches, new response categories need to be defined that can identify responses that are deeper than those conventionally defined as complete response. Recent attempts have focused on the identification of residual tumour cells in the bone marrow using flow cytometry or gene sequencing. Furthermore, sensitive imaging techniques can be used to detect the presence of residual disease outside of the bone marrow. Combining these new methods, the International Myeloma Working Group has defined new response categories of minimal residual disease negativity, with or without imaging-based absence of extramedullary disease, to allow uniform reporting within and outside clinical trials. In this Review, we clarify several aspects of disease response assessment, along with endpoints for clinical trials, and highlight future directions for disease response assessments. {\textcopyright} 2016 Elsevier Ltd},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84995917601\&doi=10.1016\%2fS1470-2045\%2816\%2930206-6\&partnerID=40\&md5=7391a1548755424ae9cdf646f73bc942},
	author = {Kumar, S. and Paiva, B. and Anderson, K.C. and Durie, B. and Landgren, O. and Moreau, P. and Munshi, N. and Lonial, S. and Blad{\'e}, J. and Mateos, M.-V. and Dimopoulos, M. and Kastritis, E. and Boccadoro, M. and Orlowski, R. and Goldschmidt, H. and Spencer, A. and Hou, J. and Chng, W.J. and Usmani, S.Z. and Zamagni, E. and Shimizu, K. and Jagannath, S. and Johnsen, H.E. and Terpos, E. and Reiman, A. and Kyle, R.A. and Sonneveld, P. and Richardson, P.G. and McCarthy, P. and Ludwig, H. and Chen, W. and Cavo, M. and Harousseau, J.-L. and Lentzsch, S. and Hillengass, J. and Palumbo, A. and Orfao, A. and Rajkumar, S.V. and Miguel, J.S. and Avet-Loiseau, H.}
}
